Effectiveness, safety, and retreatment outcomes in GEP-NET patients undergoing ¹⁷⁷Lu-based PRRT: a ten-year real-world experience.
7 affiliations
- 1Department of Nuclear Medicine Ordensklinikum Linz, Linz, Austria. [email protected].
- 2Department of Radiation Oncology Ordensklinikum Linz, Linz, Austria. [email protected].
- 3Medical Faculty, Johannes Kepler University Linz, Linz, Austria. [email protected].
- 4Medical University of Vienna, Vienna, Austria.
- 5Department of Nuclear Medicine Ordensklinikum Linz, Linz, Austria.
- 6Medical Faculty, Johannes Kepler University Linz, Linz, Austria.
- 7Department of Hematology and Medical Oncology Ordensklinikum Linz, Linz, Austria.
Abstract
Background
Peptide receptor radionuclide therapy (PRRT) using ¹⁷⁷Lu-labeled somatostatin analogues is an established and increasingly applied treatment for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). We report results focusing on effectiveness, short-term safety, and retreatment outcomes, based on ten years of clinical experience from an Austrian center of expertise, including patients referred for retreatment after prior therapy elsewhere.Methods
This retrospective study included 49 patients treated with ¹⁷⁷Lu-DOTATATE or ¹⁷⁷Lu-DOTATOC between 2014 and 2023. Subgroups included patients receiving their first PRRT course at our center (n = 45). Of this initial-treatment cohort, 9 patients subsequently underwent PRRT retreatment at our center. Additionally, 4 external patients previously treated with ⁹⁰Y-PRRT at another institution were referred for ¹⁷⁷Lu-based retreatment, resulting in a total retreatment subgroup of 13 patients. Overall survival (OS), progression-free survival (PFS), and selected laboratory toxicity parameters were evaluated according to CTCAE v5.0.Results
In the GEP-NET group, the median number of PRRT cycles was 4 with a median cumulative activity of 27.9 GBq. Median OS was 54.2 months (95% CI: 33.2-upper bound not reached), and median PFS was 24.1 months (95% CI: 11.8-36.1). PET-CT-based response assessment was available in 36 of 45 patients. Using evaluable patients as denominator, the exploratory visual SSTR-PET-CT-based objective response rate was 30.6%. Considering the entire initial-treatment cohort and assuming patients without follow-up imaging were non-responders, the ORR was 24.4%. Grade 3 or higher hematologic toxicity occurred in 4.4% of patients with one case each of grade 3 anemia and grade 4 leukopenia while no grade 3 or higher renal toxicity was observed. One patient (2%) developed myelodysplastic syndrome (MDS), followed by acute myeloid leukemia (AML). In the retreatment group (median 4 additional cycles), the median PFS was 18.1 months (95% CI: 8.6-24.6) and the ORR was 30.8% (n = 13). No grade ≥3 toxicities or hematologic malignancies were observed.Conclusion
PRRT at our institution showed clinical outcomes and a favorable short-term safety profile broadly consistent with previously published PRRT studies. These findings support the role of PRRT in routine clinical practice. Retreatment outcomes appeared encouraging in selected patients but should be interpreted as exploratory given the limited cohort size, retrospective design, and absence of formal comparative analysis.
Related
- Clinical Characteristics and Outcomes of Patients Undergoing Pericardiocentesis for Pericardial Effusion: A Single-Center Experience with Exploratory Inflammatory Biomarker Analysis
- Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)
- Real-world effectiveness and clinical outcomes of biologic therapy in severe asthma: A single-center experience from the United Arab Emirates.
- Thrombophilic Variants and Clinical Outcomes in Young Ischaemic Stroke Patients Undergoing Mechanical Thrombectomy: A Retrospective Cohort Study
- Clinical and Patient-Reported Outcomes in Non-English-Speaking Patients Undergoing Primary Total Knee Arthroplasty
BibTeX
@article{trinkl2026effectiveness,
title = {{Effectiveness, safety, and retreatment outcomes in GEP-NET patients undergoing ¹⁷⁷Lu-based PRRT: a ten-year real-world experience.}},
author = {Leonhard Trinkl and Paul Thöne and Josef Dierneder and Holger Rumpold},
journal = {BMC cancer},
year = {2026},
month = jul,
doi = {10.1186/s12885-026-16556-4},
url = {https://europepmc.org/article/MED/42907811},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Effectiveness, safety, and retreatment outcomes in GEP-NET patients undergoing ¹⁷⁷Lu-based PRRT: a ten-year real-world experience.
AU - Leonhard Trinkl
AU - Paul Thöne
AU - Josef Dierneder
AU - Holger Rumpold
PY - 2026
DA - 2026/07/01
JO - BMC cancer
DO - 10.1186/s12885-026-16556-4
UR - https://europepmc.org/article/MED/42907811
AB - Background Peptide receptor radionuclide therapy (PRRT) using ¹⁷⁷Lu-labeled somatostatin analogues is an established and increasingly applied treatment for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). We report results focusing on effectiveness, short-term safety, and retreatment outcomes, based on ten years of clinical experience from an Austrian center of expertise, including patients referred for retreatment after prior therapy elsewhere.Methods This retrospective study included 49 patients treated with ¹⁷⁷Lu-DOTATATE or ¹⁷⁷Lu-DOTATOC between 2014 and 2023. Subgroups included patients receiving their first PRRT course at our center (n = 45). Of this initial-treatment cohort, 9 patients subsequently underwent PRRT retreatment at our center. Additionally, 4 external patients previously treated with ⁹⁰Y-PRRT at another institution were referred for ¹⁷⁷Lu-based retreatment, resulting in a total retreatment subgroup of 13 patients. Overall survival (OS), progression-free survival (PFS), and selected laboratory toxicity parameters were evaluated according to CTCAE v5.0.Results In the GEP-NET group, the median number of PRRT cycles was 4 with a median cumulative activity of 27.9 GBq. Median OS was 54.2 months (95% CI: 33.2-upper bound not reached), and median PFS was 24.1 months (95% CI: 11.8-36.1). PET-CT-based response assessment was available in 36 of 45 patients. Using evaluable patients as denominator, the exploratory visual SSTR-PET-CT-based objective response rate was 30.6%. Considering the entire initial-treatment cohort and assuming patients without follow-up imaging were non-responders, the ORR was 24.4%. Grade 3 or higher hematologic toxicity occurred in 4.4% of patients with one case each of grade 3 anemia and grade 4 leukopenia while no grade 3 or higher renal toxicity was observed. One patient (2%) developed myelodysplastic syndrome (MDS), followed by acute myeloid leukemia (AML). In the retreatment group (median 4 additional cycles), the median PFS was 18.1 months (95% CI: 8.6-24.6) and the ORR was 30.8% (n = 13). No grade ≥3 toxicities or hematologic malignancies were observed.Conclusion PRRT at our institution showed clinical outcomes and a favorable short-term safety profile broadly consistent with previously published PRRT studies. These findings support the role of PRRT in routine clinical practice. Retreatment outcomes appeared encouraging in selected patients but should be interpreted as exploratory given the limited cohort size, retrospective design, and absence of formal comparative analysis.
SN - 1471-2407
ER -